PTGS2 and breast cancer: Future clinical studies will have to address if combined evaluation of E-cadherin protein, COX-2, and pGSK3βS9 could contribute to the identification of patients with metastatic BC who may benefit from combination therapies that target the PGE2 signaling pathway.